Pipeline

OKYO is focused on developing innovative GPCR-based therapies for eye diseases with significant unmet needs with a market with substantial growth potential. Specifically, the company is advancing first-in-class drug candidates aimed at treating ocular pain, dry eye disease, and uveitis. OKYO’s lead drug candidate, urcosimod, is a non-steroidal anti-inflammatory and non-opioid analgesic.